Literature DB >> 22472546

CYP3A variation, premenopausal estrone levels, and breast cancer risk.

Nichola Johnson1, Kate Walker, Lorna J Gibson, Nick Orr, Elizabeth Folkerd, Ben Haynes, Claire Palles, Ben Coupland, Minouk Schoemaker, Michael Jones, Peter Broderick, Elinor Sawyer, Michael Kerin, Ian P Tomlinson, Marketa Zvelebil, Sarah Chilcott-Burns, Katarzyna Tomczyk, Gemma Simpson, Jill Williamson, Stephen G Hillier, Gillian Ross, Richard S Houlston, Anthony Swerdlow, Alan Ashworth, Mitch Dowsett, Julian Peto, Isabel Dos Santos Silva, Olivia Fletcher.   

Abstract

BACKGROUND: Epidemiological studies have provided strong evidence for a role of endogenous sex steroids in the etiology of breast cancer. Our aim was to identify common variants in genes involved in sex steroid synthesis or metabolism that are associated with hormone levels and the risk of breast cancer in premenopausal women.
METHODS: We measured urinary levels of estrone glucuronide (E1G) using a protocol specifically developed to account for cyclic variation in hormone levels during the menstrual cycle in 729 healthy premenopausal women. We genotyped 642 single-nucleotide polymorphisms (SNPs) in these women; a single SNP, rs10273424, was further tested for association with the risk of breast cancer using data from 10 551 breast cancer case patients and 17 535 control subjects. All statistical tests were two-sided.
RESULTS: rs10273424, which maps approximately 50 kb centromeric to the cytochrome P450 3A (CYP3A) gene cluster at chromosome 7q22.1, was associated with a 21.8% reduction in E1G levels (95% confidence interval [CI] = 27.8% to 15.3% reduction; P = 2.7 × 10(-9)) and a modest reduction in the risk of breast cancer in case patients who were diagnosed at or before age 50 years (odds ratio [OR] = 0.91, 95% CI = 0.83 to 0.99; P = .03) but not in those diagnosed after age 50 years (OR = 1.01, 95% CI = 0.93 to 1.10; P = .82).
CONCLUSIONS: Genetic variation in noncoding sequences flanking the CYP3A locus contributes to variance in premenopausal E1G levels and is associated with the risk of breast cancer in younger patients. This association may have wider implications given that the most predominantly expressed CYP3A gene, CYP3A4, is responsible for metabolism of endogenous and exogenous hormones and hormonal agents used in the treatment of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22472546     DOI: 10.1093/jnci/djs156

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  20 in total

1.  Unraveling genes, hormones, and breast cancer.

Authors:  Jonine D Figueroa; Louise A Brinton
Journal:  J Natl Cancer Inst       Date:  2012-04-03       Impact factor: 13.506

2.  Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population.

Authors:  Xu Liu; Xi Huang; Shanshan Zhang; Fanglin Niu; Yongri Ouyang; Zhexing Shou; Jikui Liu
Journal:  Int J Clin Oncol       Date:  2018-09-14       Impact factor: 3.402

Review 3.  Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Authors:  Haixing Li; Jed N Lampe
Journal:  Arch Biochem Biophys       Date:  2019-08-22       Impact factor: 4.013

Review 4.  Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer.

Authors:  Tsz-Ying Lau; Hiu-Yee Kwan
Journal:  Mar Drugs       Date:  2022-05-30       Impact factor: 6.085

5.  Genetic polymorphisms of phase I metabolizing enzyme genes, their interaction with lifetime grilled and smoked meat intake, and breast cancer incidence.

Authors:  Humberto Parada; Susan E Steck; Rebecca J Cleveland; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella; Marilie D Gammon
Journal:  Ann Epidemiol       Date:  2016-11-25       Impact factor: 3.797

6.  Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.

Authors:  Nichola Johnson; Paolo De Ieso; Gabriele Migliorini; Nick Orr; Peter Broderick; Daniel Catovsky; Athena Matakidou; Timothy Eisen; Christy Goldsmith; Frank Dudbridge; Julian Peto; Isabel Dos-Santos-Silva; Alan Ashworth; Gillian Ross; Richard S Houlston; Olivia Fletcher
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

Review 7.  Cytochrome P450: Implications for human breast cancer.

Authors:  Bin Luo; Dandan Yan; Honglin Yan; Jingping Yuan
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

8.  Identification of candidate polymorphisms on stress oxidative and DNA damage repair genes related with clinical outcome in breast cancer patients.

Authors:  Patricia Rodrigues; Jessica Furriol; Begoña Bermejo; Felipe Javier Chaves; Ana Lluch; Pilar Eroles
Journal:  Int J Mol Sci       Date:  2012-12-05       Impact factor: 5.923

9.  Polymorphisms of Phase I and Phase II Enzymes and Breast Cancer Risk.

Authors:  Christina Justenhoven
Journal:  Front Genet       Date:  2012-11-28       Impact factor: 4.599

10.  Genetic variants in hormone-related genes and risk of breast cancer.

Authors:  Tess Clendenen; Anne Zeleniuch-Jacquotte; Isaac Wirgin; Karen L Koenig; Yelena Afanasyeva; Eva Lundin; Alan A Arslan; Tomas Axelsson; Asta Försti; Göran Hallmans; Kari Hemminki; Per Lenner; Nirmal Roy; Roy E Shore; Yu Chen
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.